Celsion Corporation Stock News
$1.01
3.95%
today
Nasdaq,
Apr 03, 06:21 pm CET
Celsion Corporation Stock News
Neutral
GlobeNewsWire
●
10 days ago
First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer
Neutral
Seeking Alpha
●
about one month ago
Imunon, Inc. (NASDAQ:IMNN ) Q4 2024 Results Conference Call February 26, 2025 11:00 AM ET Company Participants Peter Vozzo - ICR Healthcare, IR Stacy Lindborg - President & Chief Executive Officer Douglas Faller - Chief Medical Officer David Gaiero - Interim Chief Financial Officer Michael Tardugno - Executive Chairman Khursheed Anwer - Chief Scientific Officer Conference Call Participants Davi...
Neutral
GlobeNewsWire
●
about one month ago
IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer
Neutral
GlobeNewsWire
●
about one month ago
Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine ® technology
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
